Neuroscientific Basis of Treatment for Substance Use Disorders

Overview

Journal Noro Psikiyatr Ars

Date 2022 Dec 29

PMID 36578985

Authors

Muge Bozkurt

Affiliations

Soon will be listed here.

Abstract

Substance use disorder is a chronic and relapsing disease that burdens both the individual and the society. In addition to psychosocial treatment approaches, currently there are approved pharmacological treatment options for opioid, alcohol and tobacco use disorders, but only symptomatic treatment can be offered to patients with other substance use disorders. Advances in neuroscience and a better understanding of the addiction process offer an opportunity to create new treatment options. There is a wide range of studies, ranging from the use of drugs with different indications to the development of new pharmacological treatments, and from vaccine studies to neuromodulation techniques. Establishing novel treatment goals in addition to complete abstinence and individualizing treatment by focusing on endophenotypes may increase the treatment alternatives and the efficacy of these treatments for SUD.

Citing Articles

Addressing cortex dysregulation in youth through brain health check coaching and prophylactic brain development.

Blum K, Braverman E, Gold M, Dennen C, Baron D, Thanos P INNOSC Theranostics Pharmacol Sci. 2024; 7(2):1472.

PMID: 38766548 PMC: 11100020. DOI: 10.36922/itps.1472.

References

Haney M, Cooper Z, Bedi G, Vosburg S, Comer S, Foltin R . Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology. 2013; 38(8):1557-65. PMC: 3682150. DOI: 10.1038/npp.2013.54. View

Volkow N, Morales M . The Brain on Drugs: From Reward to Addiction. Cell. 2015; 162(4):712-25. DOI: 10.1016/j.cell.2015.07.046. View

Bozinoff N, Le Foll B . Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment. Expert Rev Respir Med. 2018; 12(9):793-804. DOI: 10.1080/17476348.2018.1507736. View

Pergolizzi Jr J, Annabi H, Gharibo C, LeQuang J . The Role of Lofexidine in Management of Opioid Withdrawal. Pain Ther. 2018; 8(1):67-78. PMC: 6513979. DOI: 10.1007/s40122-018-0108-7. View

Hassan O, Phan S, Wiecks N, Joaquin C, Bondarenko V . Outcomes of deep brain stimulation surgery for substance use disorder: a systematic review. Neurosurg Rev. 2020; 44(4):1967-1976. DOI: 10.1007/s10143-020-01415-y. View

Volkow N, Boyle M . Neuroscience of Addiction: Relevance to Prevention and Treatment. Am J Psychiatry. 2018; 175(8):729-740. DOI: 10.1176/appi.ajp.2018.17101174. View

Nestler E . From neurobiology to treatment: progress against addiction. Nat Neurosci. 2002; 5 Suppl:1076-9. DOI: 10.1038/nn945. View

Koehl J, Zimmerman D, Bridgeman P . Medications for management of opioid use disorder. Am J Health Syst Pharm. 2019; 76(15):1097-1103. DOI: 10.1093/ajhp/zxz105. View

Mann K, Roos C, Hoffmann S, Nakovics H, Lemenager T, Heinz A . Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes. Neuropsychopharmacology. 2017; 43(4):891-899. PMC: 5809801. DOI: 10.1038/npp.2017.282. View

10.

Plunk A, Syed-Mohammed H, Cavazos-Rehg P, Bierut L, Grucza R . Alcohol consumption, heavy drinking, and mortality: rethinking the j-shaped curve. Alcohol Clin Exp Res. 2013; 38(2):471-8. PMC: 3872245. DOI: 10.1111/acer.12250. View

11.

Langleben D, Ruparel K, Elman I, Loughead J, Busch E, Cornish J . Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients. Addict Biol. 2012; 19(2):262-71. DOI: 10.1111/j.1369-1600.2012.00462.x. View

12.

Coles A, Kozak K, George T . A review of brain stimulation methods to treat substance use disorders. Am J Addict. 2018; 27(2):71-91. PMC: 6034717. DOI: 10.1111/ajad.12674. View

13.

Bell J, Strang J . Medication Treatment of Opioid Use Disorder. Biol Psychiatry. 2019; 87(1):82-88. DOI: 10.1016/j.biopsych.2019.06.020. View

14.

Shen W . Anticraving therapy for alcohol use disorder: A clinical review. Neuropsychopharmacol Rep. 2018; 38(3):105-116. PMC: 7292332. DOI: 10.1002/npr2.12028. View

15.

Zalewska-Kaszubska J . Is immunotherapy an opportunity for effective treatment of drug addiction?. Vaccine. 2015; 33(48):6545-51. DOI: 10.1016/j.vaccine.2015.09.079. View

16.

Koob G, Moal M . Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci. 2005; 8(11):1442-4. DOI: 10.1038/nn1105-1442. View

17.

Miranda A, Taca A . Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment. Am J Drug Alcohol Abuse. 2017; 44(1):56-63. DOI: 10.1080/00952990.2017.1295459. View

18.

Rosenthal R, Lofwall M, Kim S, Chen M, Beebe K, Vocci F . Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial. JAMA. 2016; 316(3):282-90. DOI: 10.1001/jama.2016.9382. View

19.

Pravetoni M, Le Naour M, Tucker A, Harmon T, Hawley T, Portoghese P . Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem. 2012; 56(3):915-23. PMC: 3791856. DOI: 10.1021/jm3013745. View

20.

Allsop D, Copeland J, Lintzeris N, Dunlop A, Montebello M, Sadler C . Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014; 71(3):281-91. DOI: 10.1001/jamapsychiatry.2013.3947. View